Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers - Archive ouverte HAL Access content directly
Journal Articles Current Alzheimer Research Year : 2018

Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers

, , , , , , , (1) , , , , , , , , , , , , , , , , ,
1
Olivier Vercruysse
  • Function : Author
Claire Paquet
  • Function : Author
Audrey Gabelle
Xavier Delbeuck
  • Function : Author
Frederic Blanc
  • Function : Author
David Wallon
  • Function : Author
Julien Dumurgier
Eloi Magnin
Olivier Martinaud
  • Function : Author
Barbara Jung
  • Function : Author
Olivier Bousiges
  • Function : Author
Sylvain Lehmann
Constance Delaby
Muriel Quillard-Murain
  • Function : Author
Katell Peoc H
  • Function : Author
Jean-Louis Laplanche
  • Function : Author
Elodie Bouaziz-Amar
  • Function : Author
Didier Hannequin
  • Function : Author
Bernard Sablonniere
  • Function : Author
Luc Buee
  • Function : Author
Jacques Hugon
  • Function : Author
Susanna Schraen
  • Function : Author
Florence Pasquier
  • Function : Author
Stephanie Bombois
Katell Peoc`h
  • Function : Author

Abstract

Background: Few patients with a normal cerebrospinal fluid (CSF) biomarker profile fulfill the clinical criteria for Alzheimer disease (AD). Objective: The aim of this study was to test the hypothesis of misdiagnoses for these patients. Method: Patients from the e-PLM centers fulfilling the core clinical criteria for probable AD dementia or mild cognitive impairment due to AD (AD-MCI), with normal CSF Aβ1-42, T-tau and P-tau biomarkers and clinical follow-up, were included. Clinical and imaging data were reviewed by an independent board, from baseline (visit with clinical evaluation and CSF analysis) to the end of the follow-up, for a final diagnosis. Results: In the e-PLM cohort of 1098 AD patients with CSF analysis, 37 (3.3%) patients (20 with AD dementia core clinical criteria and 17 with AD-MCI core clinical criteria) had normal CSF biomarker profile and a clinical follow-up. All patients presented with episodic memory impairment and 27 (73%) had medial temporal lobe atrophy on MRI-scan. After a median follow-up of 36 months (range 7-74), the final diagnosis was AD MCI or dementia for 9 (24%) patients, and unlikely due to AD for 28 (76%) patients. A misdiagnosis was corrected in 18 (49%) patients (mood disorders, non-AD degenerative dementia, vascular cognitive impairment, alcohol cognitive disorders, temporal epilepsy and hippocampal sclerosis), and 10 (27%) patients had cognitive disorders of undetermined etiology. Conclusion: AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition. A clinical follow- up is particularly recommended to consider an alternative diagnosis.
AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition. A clinical follow- up is particularly recommended to consider an alternative diagnosis.
Not file

Dates and versions

hal-03630171 , version 1 (04-04-2022)

Identifiers

Cite

Olivier Vercruysse, Claire Paquet, Audrey Gabelle, Xavier Delbeuck, Frederic Blanc, et al.. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15 (7), pp.691-700. ⟨10.2174/1567205015666180110113238⟩. ⟨hal-03630171⟩

Collections

UNIV-FCOMTE
7 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More